Liu Zhi-gang, Li Ze-geng, Peng Bo
Clinical Medicine College, Anhui University of Traditional Chinese Medicine, Hefei.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Dec;31(12):1619-26.
By using the metabonomics method, to study the plasma metabonomics of the stable phase chronic obstructive pulmonary disease (COPD) patients of Fei-qi deficiency syndrome (FQDS), and of Chinese materia medica (CMM) intervention, thus exploring possibly existent biomarkers.
Forty stable phase COPD patients of FQDS were recruited as Group A. Liuwei Buqi Capsule (LWBQC) was given to them as intervention. A healthy control group (Group B, 37 cases) was set up. The pulmonary function test was performed on patients in Group B and Group A before and after intervention. The plasma metabolites were detected using high performance liquid chromatography-mass spectrometry (HPLC-MS/MS). Statistical data were analyzed using principal component analysis (PCA) and partial least squares (PLS). The original spectrum and data of plasma metabonomics were compared between the two groups. The whole spectrum amino acid metabonomics tests were performed in the two groups.
Compared with Group B, the pulmonary function significantly decreased before intervention in Group A (P < 0.05). The pulmonary function was more mildly improved after 30 days' treatment than before treatment, but still lower than it in Group B (P < 0.05). The metabolic spectrum before treatment in Group A was significantly different from Group B, but showing regressive trend to Group B after treatment. Fifteen possible disease markers were found in COPD patients of FQDS. Results of the whole spectrum of amino acid metabolomics showed different features.
The changes of metabolic spectrum and amino acids could be found in the stable phase COPD patients of FQDS using plasma metabonomics, and potential markers could be detected. The intervention of the stable phase COPD patients of FQDS by Chinese medicine could brought positive changes in the metabolic profiling and amino acid metabolism.
运用代谢组学方法,研究稳定期肺气虚证慢性阻塞性肺疾病(COPD)患者及中药干预后的血浆代谢组学,探索可能存在的生物标志物。
招募40例稳定期肺气虚证COPD患者作为A组,给予六君子胶囊(LWBQC)进行干预。设立健康对照组(B组,37例)。对B组和A组患者干预前后进行肺功能检测。采用高效液相色谱-质谱联用技术(HPLC-MS/MS)检测血浆代谢物。运用主成分分析(PCA)和偏最小二乘法(PLS)对统计数据进行分析。比较两组血浆代谢组学的原始图谱和数据。对两组进行全谱氨基酸代谢组学检测。
与B组相比,A组干预前肺功能明显下降(P<0.05)。治疗30天后肺功能改善程度较治疗前略有提高,但仍低于B组(P<0.05)。A组治疗前代谢图谱与B组有显著差异,但治疗后呈向B组回归趋势。在肺气虚证COPD患者中发现15种可能的疾病标志物。全谱氨基酸代谢组学结果显示出不同特征。
运用血浆代谢组学可发现稳定期肺气虚证COPD患者代谢图谱及氨基酸的变化,并能检测到潜在标志物。中药对稳定期肺气虚证COPD患者的干预可使代谢轮廓和氨基酸代谢产生积极变化。